ArticleTranslational cancer research2022
Construction of miRNA-mRNA network and a nomogram model of prognostic analysis for prostate cancer.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Bioinformatics and machine learning integration reveals a novel 4-gene (GFUS, ARHGAP8, NBL1, and ACTB) biomarker model for prostate cancer.Discover oncology · 2026Article
- Evaluating the prognosis of prostate cancer through metabolic pathways.Discover oncology · 2025Article
- Development and external validation of a nomogram to predict the prognosis of patients with metastatic prostate cancer who underwent radiotherapy.Gland surgery · 2024Article
- A panel based on three-miRNAs as diagnostic biomarker for prostate cancer.Frontiers in genetics · 2024Article
- Integrated analysis of the potential roles of microRNA-messenger RNA networks in prostate adenocarcinoma.Heliyon · 2023Article
- A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer.European journal of medical research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dysregulated genetic factors correlate with carcinoma progression. However, the hub miRNAs-mRNAs related to biochemical recurrence in prostate cancer remain unclear. We aim to identify potential miRNA-mRNA regulatory network and hub genes in prostate cancer. Methods: Datasets of gene expression microarray were downloaded from Gene Expression Omnibus (GEO) database for Robust Rank Aggregation (RRA), targeted gene prediction, gene function and signal pathway enrichment analyses, miRNA-mRNA regulatory network construction, core network screening, as well as validation and survival analysis were carried out by using exogenous data. Results: Prostate cancer-related differentially expressed genes were mostly related to actin filament regulation. Moreover, the cGMP-PKG signaling pathway might play a role in prostate cancer progression. As the core of microRNAs, hsa-miR-106b-5p, hsa-miR-17-5p and hsa-miR-183-5p were matched to hub genes (such as Conclusions: Hub genes were closely related to prostate cancer development and progression, which might become biomarkers for diagnosis and prognosis. This novel nomogram established could be applied to clinical prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.